Navigation Links
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Date:2/28/2011

NEW YORK, Feb. 28, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following March 2011 investor conferences:Citigroup Global Health Care Conference (New York, NY)Wednesday, March 2, 201111:00am ETCowen & Company 31st Annual Health Care Conference (Boston, MA)Monday, March 7, 2011 4:45pm ETROTH 23rd Annual OC Growth Stock Conference  (Laguna Niguel, CA)Monday, March 14, 201112:00 Noon PTEach of the presentations will be live audio webcast, and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. Archived versions of each webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with approved therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreemen
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Oct. 2, 2014   Softworld, Inc. announced today ... practice solely focused on the specific needs of pharmaceutical, ... Softworld has already been highly successful in the clinical ... capabilities to support the quality, regulatory, and validation space. ... a combination of the current Biometric team and the ...
(Date:10/2/2014)... 2, 2014   Mast Therapeutics, Inc. (NYSE ... Edwin L. Parsley , D.O. has joined the ... President.  Dr. Parsley has been actively engaged ... in February 2014.  He has served as Mast,s interim ... Medical Officer of Aires since April 2011.  Dr. Parsley ...
(Date:10/2/2014)... BOSTON , Oct. 1, 2014   Intarcia ... two of its four phase 3 clinical trials for ... through a matchstick-sized, subcutaneous osmotic mini-pump). The first trial, ... that tested the efficacy and safety of ITCA 650 ... study demonstrated ITCA 650 to be significantly superior to ...
Breaking Medicine Technology:Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 3Mast Therapeutics Announces Appointment Of Chief Medical Officer 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5
... June 20, 2011 Boston Scientific Corporation (NYSE: ... its Mustang™ PTA Balloon Catheter, a highly deliverable 0.035 ... wide range of peripheral angioplasty procedures.  The Company plans ... and other international markets. Boston Scientific ...
... Panacea Global Inc., ("the Company") (OTCQB: PANG), a biopharmaceutical ... diagnose and monitor cancer, today announced the change of the ... On June 15, 2011, the trading symbol for the Company,s ... was changed from MLXG to PANG.  This change was made ...
Cached Medicine Technology:Boston Scientific Announces Global Launch of Mustang™ PTA Balloon Catheter 2Boston Scientific Announces Global Launch of Mustang™ PTA Balloon Catheter 3Panacea Global, Inc. Files Form 8-K to Announce Name Change; Trading Symbol Changes from MLXG to PANG 2
(Date:10/2/2014)... at The University of Nottingham could lead to the ... A drug resulting from the research, published in the ... hope to sufferers of chronic pain conditions such as ... currently available. , The work, led by Dr Lucy ... collaboration with David Bates, Professor of Oncology in the ...
(Date:10/1/2014)... shown that more than 80 per cent of bowel ... study found that medicines called ,JAK inhibitors, halted tumour ... is present in more than 80 per cent of ... are in clinical trials, for diseases including rheumatoid arthritis, ... is the second-most common cancer in Australia with nearly ...
(Date:10/1/2014)... New research co-funded by the Engineering and Physical ... cyber-security of the UK,s vital industrial control systems ... the electricity grid, and the rail network. ... threats from hackers or malware infiltrating the systems ... Research Institute in Trustworthy Industrial Control Systems (RITICS), ...
(Date:10/1/2014)... suggests the adage that encourages people to keep their ... it comes to exercise. When walking, staying focused on ... it appear shorter and help people walk there faster, ... technique to walking while looking around the environment naturally, ... exercise. , "People are less interested in exercise if ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Insuranceragents.info ... find a good life insurance plan for vulnerable family ... for vulnerable family members. Providers in the family should ... will cause financial hardships for the rest of the ... of policies. Families can benefit more from temporary coverage ...
Breaking Medicine News(10 mins):Health News:Medical discovery first step on path to new painkillers 2Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2
... New findings about brain rhythms could lead to the development ... team at Massachusetts General Hospital found that a brain rhythm ... form during sleep, where it becomes more intense at certain ... being awakened by noise or other disturbances. To test ...
... (ASM) will hold its 111th General Meeting May ... meeting will feature approximately 3,000 individual scientific presentations ... expected attendance of 10,000. Microbiologists study living ... critical to human and animal health, agriculture, the ...
... a common but painful deformity of the foot, are more likely ... found. And the more severe the bunion, the more likely ... body, leading to declines in both general and foot-specific health-related quality ... develops on the side of the big toe as it leans ...
... have discovered that a natural product isolated from a traditional ... lei gong teng, and used for hundreds of years to ... control machinery in the cell. The report, published as a ... Biology, suggests that the natural product could be a ...
... HealthDay Reporter , THURSDAY, March 3 (HealthDay News) ... painkillers experience cognitive problems such as confusion, disorientation and ... cancer patients from 17 health-care centers around Europe indicated ... morphine scored lower on observer-rated mental tests measuring orientation ...
... vast literature on cancer to produce a next-generation view ... cells. These hallmarks of the disease provide a ... influence biomedical researchers in their quest for new cancer ... Hanahan of cole Polytechnique Fdrale in Switzerland and Robert ...
Cached Medicine News:Health News:Particular Brain Rhythm in Sleep Makes You More Vulnerable to Disturbances 2Health News:American Society for Microbiology to host 111th General Meeting in New Orleans 2Health News:Solving a traditional Chinese medicine mystery 2Health News:Solving a traditional Chinese medicine mystery 3Health News:Study Finds Third of Cancer Patients on Opioids Are Confused 2Health News:Study Finds Third of Cancer Patients on Opioids Are Confused 3Health News:In search of cancer's common ground: A next-generation view 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: